ORIC Pharmaceuticals, Inc.
ORIC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $29 | $31 | $25 | $32 |
| G&A Expenses | $8 | $9 | $8 | $0 |
| SG&A Expenses | $8 | $9 | $8 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $37 | $39 | $33 | $39 |
| Operating Income | -$37 | -$39 | -$33 | -$40 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $3 | $3 | $3 |
| Pre-Tax Income | -$33 | -$36 | -$30 | -$36 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$33 | -$36 | -$30 | -$36 |
| % Margin | – | – | – | – |
| EPS | -0.33 | -0.47 | -0.42 | -0.51 |
| % Growth | 29.8% | -11.9% | 17.6% | – |
| EPS Diluted | -0.33 | -0.47 | -0.42 | -0.51 |
| Weighted Avg Shares Out | 99 | 78 | 71 | 71 |
| Weighted Avg Shares Out Dil | 99 | 78 | 71 | 71 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$32 | -$39 | -$32 | -$36 |
| % Margin | – | – | – | – |